WO2015169953A1 - Méthode de traitement d'un gliome à l'aide de composés thiénotriazolodiazépine - Google Patents

Méthode de traitement d'un gliome à l'aide de composés thiénotriazolodiazépine Download PDF

Info

Publication number
WO2015169953A1
WO2015169953A1 PCT/EP2015/060203 EP2015060203W WO2015169953A1 WO 2015169953 A1 WO2015169953 A1 WO 2015169953A1 EP 2015060203 W EP2015060203 W EP 2015060203W WO 2015169953 A1 WO2015169953 A1 WO 2015169953A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
carbon number
solid dispersion
alkyl
formula
Prior art date
Application number
PCT/EP2015/060203
Other languages
English (en)
Inventor
Noel KAY
Ouafik L´HOUCINE
Original Assignee
Oncoethix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix Gmbh filed Critical Oncoethix Gmbh
Publication of WO2015169953A1 publication Critical patent/WO2015169953A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne une méthode permettant de traiter un gliome chez un mammifère, qui consiste à administrer une dispersion solide comprenant un composé de thiénotriazolodiazépine amorphe de formule (1), ou un hydrate, un solvate ou un sel pharmaceutiquement acceptable de ce composé. Dans la formule (1), R1 représente un groupe alkyle ayant de 1 à 4 atomes de carbone, R2 représente un atome d'hydrogène, un atome d'halogène ou un groupe alkyle ayant de 1 à 4 atomes de carbone facultativement substitué par un atome d'halogène ou un groupe hydroxyle, R3 représente un atome d'halogène, un groupe phényle facultativement substitué par un atome d'halogène, un groupe alkyle ayant de 1 à 4 atomes de carbone, un groupe alcoxy ayant de 1 à 4 atomes de carbone ou un groupe cyano ;— NR5─(CH2)m─R6 où R5 représente un atome d'hydrogène ou un groupe alkyle ayant de 1 à 4 atomes de carbone, m est un nombre entier compris entre 0 et 4, et R6 représente un groupe phényle ou pyridyle facultativement substitué par un atome d'halogène; ou bien —NR7—CO—(CH2)n—R8 où R7 représente un atome d'hydrogène ou un groupe alkyle comprenant de 1 à 4 atomes de carbone, n est un nombre entier compris entre 0 et 2, et R8 représente un groupe phényle ou pyridyle facultativement substitué par un atome d'halogène, et R4 représente ─(CH2)a─CO─NH—R9 où a représente un nombre entier compris entre 1 et 4, et R9 représente un groupe alkyle ayant de 1 à 4 atomes de carbone; un groupe hydroxyalkyle ayant de 1 à 4 atomes de carbone ; un groupe alcoxy ayant de 1 à 4 atomes de carbone; ou un groupe phényle ou pyridyle facultativement substitué par un groupe alkyle ayant de 1 à 4 atomes de carbone, un groupe alcoxy ayant de 1 à 4 atomes de carbone, un groupe amino ou hydroxyle ou — (CH2)b— COOR10 où b représente un nombre entier compris entre 1 et 4, et R10 représente un groupe alkyle ayant de 1 à 4 atomes de carbone.
PCT/EP2015/060203 2014-05-08 2015-05-08 Méthode de traitement d'un gliome à l'aide de composés thiénotriazolodiazépine WO2015169953A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201461990462P 2014-05-08 2014-05-08
US61/990,462 2014-05-08
US201462012125P 2014-06-13 2014-06-13
US62/012,125 2014-06-13
US201462080739P 2014-11-17 2014-11-17
US62/080,739 2014-11-17
US201462086449P 2014-12-02 2014-12-02
US62/086,449 2014-12-02

Publications (1)

Publication Number Publication Date
WO2015169953A1 true WO2015169953A1 (fr) 2015-11-12

Family

ID=53175494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/060203 WO2015169953A1 (fr) 2014-05-08 2015-05-08 Méthode de traitement d'un gliome à l'aide de composés thiénotriazolodiazépine

Country Status (1)

Country Link
WO (1) WO2015169953A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9533997B2 (en) 2013-07-08 2017-01-03 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US9540368B2 (en) 2014-04-23 2017-01-10 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US9624241B2 (en) 2013-03-15 2017-04-18 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9777003B2 (en) 2013-12-19 2017-10-03 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US10189832B2 (en) 2016-06-20 2019-01-29 Incyte Corporation Crystalline solid forms of a BET inhibitor
US10329305B2 (en) 2015-10-29 2019-06-25 Incyte Corporation Amorphous solid form of a BET protein inhibitor
US11660280B2 (en) 2017-09-20 2023-05-30 Oklahoma Medical Research Foundation Treatment of drug resistant gliomas
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090012064A1 (en) 2000-06-16 2009-01-08 Kazuyoshi Sagara Compositions controlling pH range of release and/or release rate
EP2239264A1 (fr) * 2007-12-28 2010-10-13 Mitsubishi Tanabe Pharma Corporation Agent antitumoral
US20140107107A1 (en) * 2012-09-28 2014-04-17 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090012064A1 (en) 2000-06-16 2009-01-08 Kazuyoshi Sagara Compositions controlling pH range of release and/or release rate
EP2239264A1 (fr) * 2007-12-28 2010-10-13 Mitsubishi Tanabe Pharma Corporation Agent antitumoral
US20100286127A1 (en) 2007-12-28 2010-11-11 Mitsubishi Tanabe Pharma Corporation Antitumor agent
US20140107107A1 (en) * 2012-09-28 2014-04-17 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recentbreakthroughs", J. PHARM. SCI., vol. 88, 1999, pages 1058 - 1066
CARREIRA, E. M.; KVAERNO, L.: "Classics in Stereoselective Synthesis", 2009, WILEY-VCH
CHENG ZHIXIANG ET AL: "Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma", CLINICAL CANCER RESEARCH, vol. 19, no. 7, April 2013 (2013-04-01), pages 1748 - 1759, XP002741054 *
CHIOU WL; RIEGELMAN S: "Pharmaceutical applications of solid dispersion systems", J. PHARM. SCI., vol. 60, 1971, pages 1281 - 1302, XP009027674, DOI: doi:10.1002/jps.2600600902
DENIS, G.V.: "Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation", DISCOV MED, vol. 10, 2010, pages 489 - 499, XP009186550
FRIEDMAN ET AL: "Temozolomide and treatment of malignant glioma.", CLINICAL CANCER RESEARCH, vol. 6, no. 7, 1 July 2000 (2000-07-01), pages 2585 - 2597, XP055047738, ISSN: 1078-0432 *
HÉRAIT, P. ET AL.: "BET-bromodomain inhibitor OTX015 shows clinically menaingful activity at non-doxic doses : Interim results of an ongoing phase I trial in hematological malignancies", 7 April 2014 (2014-04-07), Webcast of the American Association for Cancer Resesarch Annual Meeting 2014, 5-9 April 2014, San Diego, CA, Philadelphia, pages 1 - 40, XP002741053, Retrieved from the Internet <URL:http://webcast.aacr.org/console/player/23166?mediaType=audio&> [retrieved on 20150616] *
JOHANNES H. SCHULTE: "BET protein inhibitor OTX015 has selective anti-tumoral activityin preclinical models of MYCN-amplified neuroblastoma", 9 April 2014 (2014-04-09), 105th AMERICAN ASSOCIATION for CANCER RESEARCH Annual Meeting 5-9 april 2014, San Diego, CA, Philadelphia, XP002741052, Retrieved from the Internet <URL:http://www.oncoethix.com/wp-content/uploads/2014/05/AACR-5-Neuroblastoma.pdf> [retrieved on 20150616] *
KAY NOEL, ET AL.: "Development of the BET Bromodomain Inhibitor OTX015", 23 October 2013 (2013-10-23), AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, October 19-23, 2013, XP002741051, Retrieved from the Internet <URL:http://www.oncoethix.com/wp-content/uploads/2014/04/OTX015-poster-EORTC-NCI-AACR-New-Targets-2013-Noel-et-al-MTPC-pharmacology-info.pdf> [retrieved on 20150616] *
LEUNER C; DRESSMAN J: "Improving drug solubility for oral delivery using solid dispersions", EUR. J. PHARM. BIOPHARM., vol. 50, 2000, pages 47 - 60, XP004257179, DOI: doi:10.1016/S0939-6411(00)00076-X
PASTORI CHIARA ET AL: "BET bromodomain proteins are required for glioblastoma cell proliferation.", EPIGENETICS : OFFICIAL JOURNAL OF THE DNA METHYLATION SOCIETY APR 2014, vol. 9, no. 4, April 2014 (2014-04-01), pages 611 - 620, XP002741055, ISSN: 1559-2308 *
STEVEN G. SMITH ET AL: "Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors", CHEMISTRY & BIOLOGY, vol. 21, no. 5, 1 May 2014 (2014-05-01), pages 573 - 583, XP055196352, ISSN: 1074-5521, DOI: 10.1016/j.chembiol.2014.03.004 *
VASCONCELOS T; SARMENTO B; COSTA P: "Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs", DRUG DISCOVERY TODAY, vol. 12, 2007, pages 1068 - 1075, XP022370275

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624241B2 (en) 2013-03-15 2017-04-18 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10464947B2 (en) 2013-03-15 2019-11-05 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US11498926B2 (en) 2013-03-15 2022-11-15 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10919912B2 (en) 2013-03-15 2021-02-16 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US9938294B2 (en) 2013-03-15 2018-04-10 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9850257B2 (en) 2013-07-08 2017-12-26 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9533997B2 (en) 2013-07-08 2017-01-03 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US9737516B2 (en) 2013-11-26 2017-08-22 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9918990B2 (en) 2013-11-26 2018-03-20 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9777003B2 (en) 2013-12-19 2017-10-03 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US10442803B2 (en) 2013-12-19 2019-10-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US11091484B2 (en) 2013-12-19 2021-08-17 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US11059821B2 (en) 2014-04-23 2021-07-13 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US10781209B2 (en) 2014-04-23 2020-09-22 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US11702416B2 (en) 2014-04-23 2023-07-18 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US9540368B2 (en) 2014-04-23 2017-01-10 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US10472358B2 (en) 2014-04-23 2019-11-12 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US9957268B2 (en) 2014-04-23 2018-05-01 Incyte Corporation 1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US10618910B2 (en) 2014-09-15 2020-04-14 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9834565B2 (en) 2014-09-15 2017-12-05 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10227359B2 (en) 2014-09-15 2019-03-12 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US10858372B2 (en) 2015-10-29 2020-12-08 Incyte Corporation Amorphous solid form of a BET protein inhibitor
US10329305B2 (en) 2015-10-29 2019-06-25 Incyte Corporation Amorphous solid form of a BET protein inhibitor
US10626114B2 (en) 2016-06-20 2020-04-21 Incyte Corporation Crystalline solid forms of a BET inhibitor
US10189832B2 (en) 2016-06-20 2019-01-29 Incyte Corporation Crystalline solid forms of a BET inhibitor
US11091480B2 (en) 2016-06-20 2021-08-17 Incyte Corporation Crystalline solid forms of a BET inhibitor
US11377446B2 (en) 2016-06-20 2022-07-05 Incyte Corporation Crystalline solid forms of a BET inhibitor
US11660280B2 (en) 2017-09-20 2023-05-30 Oklahoma Medical Research Foundation Treatment of drug resistant gliomas
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Similar Documents

Publication Publication Date Title
AU2013340483B2 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2015169953A1 (fr) Méthode de traitement d&#39;un gliome à l&#39;aide de composés thiénotriazolodiazépine
WO2015018522A1 (fr) Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
US9757385B2 (en) Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
US9956228B2 (en) Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
EP3137086A1 (fr) Methode de traitement de lymphome non hodgkinien resistant, de medulloblastome et/ou de cancer bronchopulmonaire non a petites cellules alk+ a l&#39;aide de composes de thienotriazolodiazepine
US9968619B2 (en) Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
KR20160037201A (ko) Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
US9901583B2 (en) Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
WO2016030509A1 (fr) Méthodes de traitement de la leucémie myéloïde aiguë, ou de la leucémie lymphoïde aiguë à l&#39;aide de compositions pharmaceutiques contenant des composés de thiénotriazolodiazépine
WO2015018520A1 (fr) Inhibiteur bet-brd représentant un nouvel agent pour un lymphome anaplasique à grandes cellules alk positif
US9820992B2 (en) Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2015018523A1 (fr) Nouvel inhibiteur de bet-brd pour le traitement de tumeurs solides
WO2015168587A1 (fr) Procédé de traitement de myélome multiple résistant et de lymphome des cellules du manteau à l&#39;aide de composés de thiénotriazolodiazépine
WO2016026912A1 (fr) Méthode de traitement de lymphomes à l&#39;aide de composés thiénotriazolodiazépine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15722170

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15722170

Country of ref document: EP

Kind code of ref document: A1